BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Status unconfirmed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00039156

Run by

Theradex

Starts

2002-01-01

Last updated by the study team

2008-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Veterans Affairs Medical Center - Shreveport — Shreveport, Louisiana, United States
• Louisiana State University Health Sciences Center - Shreveport — Shreveport, Louisiana, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• HemOnCare, P.C. — Brooklyn, New York, United States
• North Shore University Hospital — Manhasset, New York, United States
• State University of New York - Upstate Medical University — Syracuse, New York, United States
• Albert Einstein Clinical Cancer Center — The Bronx, New York, United States
• New York Medical College — Valhalla, New York, United States
• West Clinic — Memphis, Tennessee, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• Cross Cancer Institute — Edmonton, Alberta, Canada
• St. Paul's Hospital - Vancouver — Vancouver, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.